Foghorn Therapeutics Inc. (FHTX)
FHTXNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$2.04
+0.1700 (+9.09%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $121.15m
- P/E
- –
- EPS, last 4 quarters
- $-0.9800
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.79 to $7.61
- Average volume
- 867.9k
- Previous close
- $1.87
Analysts
7 coveringHold2 buy, 5 hold, 0 sell
Targets a year out average $5.00, +145.1% from here
Earnings
next estimate $-0.2300Next report Nov 11, 2026
Sep 2025
+19.4%
Dec 2025
-21.4%
Mar 2026
-3.6%
Jun 2026
+56.5%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $8.15m | $9.25m | $3.27m | $16.07m |
| Gross profit | $8.15m | $9.25m | $3.27m | $16.07m |
| Operating income | -$18.50m | -$23.88m | -$21.57m | -$8.80m |
| Net income | -$15.85m | -$21.66m | -$19.88m | -$7.19m |
Last four quarters: revenue $36.74m, margin -175.8%, free cash flow –
News
4 latest- Foghorn Therapeutics Inc. to Participate in Major Upcoming Healthcare Conferences in 2025Quiver Quantitative · May 22, 2025
- Foghorn Therapeutics Elects Neil Gallagher, M.D., Ph.D., and Stuart Duty to Board of DirectorsQuiver Quantitative · May 1, 2025
- Foghorn Therapeutics Advances FHD-909 in Phase 1 Trial for SMARCA4 Mutated Cancers with Promising Preclinical Data for Combination TherapiesQuiver Quantitative · Apr 28, 2025
- Foghorn Therapeutics Continues Enrollment in Phase 1 Trial of First-in-Class SMARCA2 Inhibitor FHD-909 for NSCLC and Reports Strong Financial OutlookQuiver Quantitative · Mar 6, 2025
The company
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- foghorntx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.